Department of Diabetes and Endocrinology, Skåne University Hospital, Malmö, Sweden
Search for other papers by B Shahida in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Malmö, Sweden
Search for other papers by P Sahlstrand Johnson in
Google Scholar
PubMed
Search for other papers by R Jain in
Google Scholar
PubMed
Department of Plastic Surgery, Skåne University Hospital, Malmö, Sweden
Search for other papers by H Brorson in
Google Scholar
PubMed
Department of Ophthalmology, Skåne University Hospital, Malmö, Sweden
Search for other papers by P Åsman in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Skåne University Hospital, Malmö, Sweden
Search for other papers by M Lantz in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Skåne University Hospital, Malmö, Sweden
Search for other papers by T Planck in
Google Scholar
PubMed
as an autoantigen and is expressed by both preadipocytes and adipocytes in orbital tissue ( 1 , 2 ) as well as in the thyroid. Other autoantigens, such as the insulin-like growth factor 1 (IGF-1) receptor have been suggested to be involved in the
Search for other papers by Sheila Leone in
Google Scholar
PubMed
Search for other papers by Lucia Recinella in
Google Scholar
PubMed
Search for other papers by Annalisa Chiavaroli in
Google Scholar
PubMed
Search for other papers by Claudio Ferrante in
Google Scholar
PubMed
Search for other papers by Giustino Orlando in
Google Scholar
PubMed
Search for other papers by Michele Vacca in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Luigi Brunetti in
Google Scholar
PubMed
Introduction Growth hormone (GH)-releasing hormone (GHRH), GH and insulin-like growth factor-1 (IGF-1), in addition to their recognised metabolic and endocrine effects, play a pivotal role in brain functions ( 1 , 2 ). Serum GH and IGF-1
Search for other papers by Jin Kyu Oh in
Google Scholar
PubMed
Search for other papers by Young Jae Im in
Google Scholar
PubMed
Search for other papers by Kwanjin Park in
Google Scholar
PubMed
Search for other papers by Jae-Seung Paick in
Google Scholar
PubMed
underlying molecular mechanisms have not been described, the GH–insulin-like growth factor 1 (IGF1) axis is a proactive mediator of the actions of testosterone and its potent derivative dihydrotestosterone. Accordingly, stimulation of IGF1 signalling
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
and or radiotherapy at our institution. After treatment, patients who had suppressible GH OGTT (<1 ng/ml) were subjected to insulin-induced hypoglycemia (IIH). GHD was defined as peak GH level ≤3 ng/ml during IIH and insulin-like growth factor 1 (IGF1
Universitat Oberta Catalunya (UOC), Barcelona, Spain
Search for other papers by Guillem Cuatrecasas in
Google Scholar
PubMed
Univ Autònoma de Barcelona, Cerdanyola del Vallès, Spain
Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain
Search for other papers by Hatice Kumru in
Google Scholar
PubMed
Search for other papers by M Josep Coves in
Google Scholar
PubMed
Univ Autònoma de Barcelona, Cerdanyola del Vallès, Spain
Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain
Search for other papers by Joan Vidal in
Google Scholar
PubMed
cause (43.7%). Male/female ratio stands at 3.9/1, tetraplegia (cervical lesions) accounts for 38.5% of the cases and complete injuries affect 56.7% of the patients ( 6 ). As known, GH mediates its action mainly on the liver acting through IGF1
Search for other papers by Dan Liang in
Google Scholar
PubMed
Search for other papers by Han Chen in
Google Scholar
PubMed
Search for other papers by Li-Yong Zhong in
Google Scholar
PubMed
/mL). Impairment to growth hormone–insulin-like growth factor-1 (GH/IGF1): children with growth retardation or adults with obvious hypometabolic syndrome had IGF1 levels below 2 s.d. than their peers and had additional pituitary hormone deficiencies. Impairment
Search for other papers by Patrizia Bruzzi in
Google Scholar
PubMed
Search for other papers by Silvia Vannelli in
Google Scholar
PubMed
Search for other papers by Emanuela Scarano in
Google Scholar
PubMed
Search for other papers by Natascia Di Iorgi in
Google Scholar
PubMed
Search for other papers by Maria Parpagnoli in
Google Scholar
PubMed
Search for other papers by MariaCarolina Salerno in
Google Scholar
PubMed
Search for other papers by Marco Pitea in
Google Scholar
PubMed
Search for other papers by Maria Elisabeth Street in
Google Scholar
PubMed
Search for other papers by Andrea Secco in
Google Scholar
PubMed
Search for other papers by Adolfo Andrea Trettene in
Google Scholar
PubMed
Search for other papers by Malgorzata Wasniewska in
Google Scholar
PubMed
Search for other papers by Nicola Corciulo in
Google Scholar
PubMed
Search for other papers by Gianluca Tornese in
Google Scholar
PubMed
Search for other papers by Maria Felicia Faienza in
Google Scholar
PubMed
Search for other papers by Maurizio Delvecchio in
Google Scholar
PubMed
Search for other papers by Simona Filomena Madeo in
Google Scholar
PubMed
Search for other papers by Lorenzo Iughetti in
Google Scholar
PubMed
verified and collected at each study time. All patients were submitted to rhGH treatment according to the Italian Agency for Drugs guidelines ( 25 ). Biochemical analysis Fasting glucose, insulin and insulin-like growth factor 1 (IGF1) values were
Search for other papers by Imane Benabbad in
Google Scholar
PubMed
Search for other papers by Myriam Rosilio in
Google Scholar
PubMed
Search for other papers by Maité Tauber in
Google Scholar
PubMed
Search for other papers by Emmanuel Paris in
Google Scholar
PubMed
Search for other papers by Anne Paulsen in
Google Scholar
PubMed
Search for other papers by Lovisa Berggren in
Google Scholar
PubMed
Search for other papers by Hiren Patel in
Google Scholar
PubMed
Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Robert-Debré, Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, France
Search for other papers by Jean-Claude Carel in
Google Scholar
PubMed
Search for other papers by the Phoenix Study Group in
Google Scholar
PubMed
( 17 ) and confirmed by a centralised bone age reading. Patients were excluded if they had GH deficiency (defined as peak GH ≤20 IU/L in each of two stimulation tests), had insulin-like growth factor (IGF)-I SDS >3, were born small for gestational age
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Search for other papers by Feng Gu in
Google Scholar
PubMed
Search for other papers by Marcello D Bronstein in
Google Scholar
PubMed
Search for other papers by Thierry C Brue in
Google Scholar
PubMed
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Search for other papers by Ilan Shimon in
Google Scholar
PubMed
Search for other papers by Aart J van der Lely in
Google Scholar
PubMed
Search for other papers by Shoba Ravichandran in
Google Scholar
PubMed
Search for other papers by Albert Kandra in
Google Scholar
PubMed
Search for other papers by Alberto M Pedroncelli in
Google Scholar
PubMed
Search for other papers by Annamaria A L Colao in
Google Scholar
PubMed
Introduction Acromegaly is a chronic endocrine disorder typically caused by a benign tumor of the pituitary gland ( 1 ), which hypersecretes growth hormone (GH) with subsequent secretion of insulin-like growth factor I (IGF-I). Long
Search for other papers by Yuanyuan Li in
Google Scholar
PubMed
Search for other papers by Dongmei Li in
Google Scholar
PubMed
Search for other papers by Xingbo Cheng in
Google Scholar
PubMed
metabolism through insulin signalling-related pathways. hPL can stimulate insulin-like growth factor (IGF), insulin, adrenocortical hormone and pulmonary surfactant (PS) and enhance the acquisition of glucose and amino acid in the foetus to facilitate its